Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons
Open Access
- 14 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e537-e539
Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19–directed therapy.Keywords
This publication has 6 references indexed in Scilit:
- Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/RitonavirResearch Square, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19Mayo Clinic Proceedings, 2021
- Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant RecipientsOpen Forum Infectious Diseases, 2021
- A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19Mayo Clinic Proceedings, 2021
- Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohortProceedings of the National Academy of Sciences, 2021